CA3061480A1 - Formulation of nanostructured gels for increased agent loading and adhesion - Google Patents

Formulation of nanostructured gels for increased agent loading and adhesion Download PDF

Info

Publication number
CA3061480A1
CA3061480A1 CA3061480A CA3061480A CA3061480A1 CA 3061480 A1 CA3061480 A1 CA 3061480A1 CA 3061480 A CA3061480 A CA 3061480A CA 3061480 A CA3061480 A CA 3061480A CA 3061480 A1 CA3061480 A1 CA 3061480A1
Authority
CA
Canada
Prior art keywords
gel
gel composition
gelator
agents
ascorbyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3061480A
Other languages
English (en)
French (fr)
Inventor
Derek G. Van Der Poll
Dominick J. Blasioli
Gregory T. Zugates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alivio Therapeutics Inc
Original Assignee
Blasioli Dominick J
Van Der Poll Derek G
Alivio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blasioli Dominick J, Van Der Poll Derek G, Alivio Therapeutics Inc filed Critical Blasioli Dominick J
Publication of CA3061480A1 publication Critical patent/CA3061480A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3061480A 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion Pending CA3061480A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502872P 2017-05-08 2017-05-08
US62/502,872 2017-05-08
PCT/US2018/031654 WO2018208822A1 (en) 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion

Publications (1)

Publication Number Publication Date
CA3061480A1 true CA3061480A1 (en) 2018-11-15

Family

ID=62223333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3061480A Pending CA3061480A1 (en) 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion

Country Status (6)

Country Link
US (2) US10881745B2 (https=)
EP (1) EP3621594A1 (https=)
JP (4) JP7211974B2 (https=)
AU (2) AU2018266131B2 (https=)
CA (1) CA3061480A1 (https=)
WO (1) WO2018208822A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136635A1 (en) * 2019-04-11 2020-10-15 Convatec Technologies Inc. Superporous hydrogels, methods of making the same, and articles incorporating the same
CN111781128B (zh) * 2020-06-15 2023-07-07 迪瑞医疗科技股份有限公司 一种尿分析仪用鞘液及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2417494A1 (fr) 1978-02-16 1979-09-14 Bottu Nouvelles compositions analgesiques et antipyretiques contenant un derive de paracetamol
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
JP3439481B2 (ja) * 1995-11-15 2003-08-25 生化学工業株式会社 光架橋ヒアルロン酸ゲルおよびその製造法
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
FR2794998B1 (fr) 1999-06-21 2001-07-27 Oreal Organogels et leurs utilisations notamment cosmetiques
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US20050084470A1 (en) 2003-10-15 2005-04-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care and cleansing compositions containing oil seed product
CA2544814C (en) 2003-11-12 2013-05-14 Applied Nanosystems B.V. Non-symmetrical gelling agent
ES2380340T3 (es) 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
US7410950B2 (en) * 2004-04-01 2008-08-12 Board Of Regents, The University Of Texas System Peptides of CaV2.2 that inhibit pain
EP1750671B1 (en) 2004-06-03 2008-10-15 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
FR2871701B1 (fr) 2004-06-21 2006-09-22 Centre Nat Rech Scient Cnrse Biomateriaux bioactifs pour le relarguage controle de principes actifs
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP1800694A1 (en) 2005-12-23 2007-06-27 Applied NanoSystems B.V. Controlled release gels
EP1991688B1 (en) 2006-02-10 2019-05-01 DuPont Tate & Lyle Bio Products Company, LLC Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol
EP1991515A4 (en) * 2006-02-10 2013-03-06 Dupont Tate & Lyle Bio Products Company Llc BIOLOGICAL SOURCE AND ITS CONJUGATES AS NATURAL AND NON-BREATHING SOLVENTS FOR BIOMASS EXTRACTS, SCENT CONCENTRATES AND OILS
US8968784B2 (en) 2006-05-22 2015-03-03 Research Foundation Of The City University Of New York Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery
US20080021068A1 (en) * 2006-07-24 2008-01-24 Akorn, Inc. Aqueous gel formulation and method for inducing topical anesthesia
JP5358574B2 (ja) * 2007-08-17 2013-12-04 アルション セラピューティクス， インコーポレイテッド 高濃度の局所麻酔薬調合物
WO2009029543A1 (en) 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
JP5724108B2 (ja) * 2009-04-22 2015-05-27 メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ 凍結乾燥組成物
AU2015200633A1 (en) * 2009-05-04 2015-02-26 Zars Pharma, Inc. Methods for treating pains associated with neuroma, nerve entrapment, and other conditions
CA2770490C (en) * 2009-08-11 2024-04-16 The Johns Hopkins University Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
CN102834096A (zh) * 2010-01-14 2012-12-19 卢福研究公司 用于疼痛控制的固态成型局部麻醉制剂
EP2361640A1 (en) 2010-02-25 2011-08-31 Université de Liège Cell cultivation in chitosan alginate hydrogel beads
MX2012011261A (es) * 2010-04-01 2012-12-05 Pharmanest Ab Composiciones bioadhesivas de anestesicos locales.
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
GB201020193D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
ES2390428B1 (es) * 2011-04-15 2013-10-01 Universidad De Almería Preparado de bacterias probióticas para su administración oral a peces cultivados basado en la encapsulación en hidrogeles de alginato.
CN104582826B (zh) 2012-06-25 2018-06-05 日产化学工业株式会社 分散液及水凝胶形成方法
EP2968109A2 (en) 2012-09-14 2016-01-20 Cipla Limited Topical pharmaceutical composition comprising tenofovir, an antibacterial agent and, optonally ciclopirox
EP2928513B1 (en) 2012-12-07 2018-06-06 Kansas State University Research Foundation Peptide-albumin hydrogel properties and its applications
EP2968135A4 (en) 2013-03-14 2016-10-26 Massachusetts Inst Technology INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES
US9789073B2 (en) * 2013-03-14 2017-10-17 Pathak Holdings, Llc Compositions, methods and devices for local drug delivery
US20150297731A1 (en) * 2014-04-21 2015-10-22 National Yang-Ming University Thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof
US9452178B1 (en) * 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US20170360912A1 (en) * 2014-12-17 2017-12-21 Socovar, L.P. Chitosan-based hydrogel and applications thereof.
EP4279064A3 (en) * 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
EP3359128A1 (en) 2015-10-08 2018-08-15 The Brigham and Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
US20170319500A1 (en) 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Self-assembled gels for controlled delivery of biologics and labile agents
US10568840B2 (en) 2016-05-06 2020-02-25 The Brigham And Women's Hospital, Inc. Self assembled gels for controlled delivery of encapsulated agents to cartilage
US20180050055A1 (en) * 2016-08-16 2018-02-22 Hafiz Ahmed Exploiting nutrient deprivation for modulation of glycosylation - research diagnostic, therapeutic, and biotechnology applications
EP3335695B1 (en) * 2016-12-15 2020-02-05 UPM-Kymmene Corporation A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose

Also Published As

Publication number Publication date
JP2023041861A (ja) 2023-03-24
US20210196836A1 (en) 2021-07-01
JP7211974B2 (ja) 2023-01-24
JP2023168587A (ja) 2023-11-24
JP2020519635A (ja) 2020-07-02
AU2018266131B2 (en) 2021-07-29
AU2018266131A1 (en) 2020-01-02
US10881745B2 (en) 2021-01-05
AU2021240143B2 (en) 2023-10-19
AU2021240143A1 (en) 2021-10-28
US20180318442A1 (en) 2018-11-08
JP2022103299A (ja) 2022-07-07
WO2018208822A1 (en) 2018-11-15
EP3621594A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
AU2016335846B2 (en) Stabilized assembled nanostructures for delivery of encapsulated agents
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
US20170319500A1 (en) Self-assembled gels for controlled delivery of biologics and labile agents
US20230364014A1 (en) Self-assembled gels for controlled delivery of biologics and methods of making thereof
CN102802624A (zh) 药物的纳米分散体以及它的制备方法
JP2023168587A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
WO2020123551A1 (en) Stable formulations of anesthetics and associated dosage forms
JPH0768130B2 (ja) 微粒子化薬剤
CN102227210B (zh) 亲脂性物质溶液,特别是药物溶液

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191024

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240715

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240909

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241108

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230